May 2026 - Page 7 of 21

BOSCHLTD – Bosch Limited – Q4 FY26 Financial Results – 20-May-26

Bosch India’s FY26 confirms a cash‑rich industrial compounding low‑mid teens revenue, with ~17% underlying earnings growth post divestiture gain. Risks: commodity cost pressures, receivables velocity, and tax normalization. Overcapitalized balance sheet (₹83,797 Mio treasury, negligible debt) makes capital allocation discipline the key re‑rating driver.

1–2 minutes

🔍 Observations

Topline

Revenue grew 10.8% YoY to ₹200,347 Mio in FY26, crossing the ₹200 Bn milestone; Q4FY26 accelerated to 13.3% YoY, signalling momentum building into year-end.
Automotive products — 88.9% of net revenues — drove growth at 14.5% YoY (₹178,074 Mio vs ₹155,489 Mio); Consumer goods grew a modest 6.4%.
“Others” segment revenue collapsed 49.5% YoY (₹8,486 Mio to ₹4,285 Mio), reflecting the deliberate divestiture of specified businesses rather than organic decline.

Bottomline

Reported PAT jumped 37.6% YoY to ₹27,700 Mio, but ₹5,560 Mio in pre-tax exceptional gains (divestiture proceeds) inflate this; adjusted PAT grew ~16.9% to ~₹23,530 Mio.
EPS (basic) rose to ₹940.27 from ₹683.25 — reported basis; underlying earnings quality is solid even after stripping out the exceptional.
Q4FY26 PAT of ₹5,685 Mio grew 2.7% YoY and 6.8% QoQ, a clean quarter with no exceptional items.

Margins

EBITDA margin (excl. exceptional) expanded marginally to 17.5% from 17.3% — a tight band suggesting cost discipline offset input cost pressures.
Automotive EBIT margin held flat at 14.4% YoY despite 14.5% revenue growth — volume-driven profit expansion with no margin dilution.
Q4FY26 EBITDA margin contracted to 16.9% vs 18.0% in Q4FY25, partly from higher raw material costs (Q4 RM+traded goods: ₹35,710 Mio vs ₹30,242 Mio in Q4FY25, +18.1%).

Growth Trajectory

Three-year revenue CAGR context: crossing ₹200 Bn on a consolidated basis reflects steady compounding in the mid-teens in Automotive — structurally tied to India’s vehicle production cycle.
Automotive EBIT grew 13.8% YoY (₹22,467 Mio to ₹25,570 Mio) in line with segment revenue — consistent conversion, no margin surprises.
Consumer goods EBIT grew 7.6% (₹1,130 Mio to ₹1,216 Mio) — low-margin, slow-growth segment; EBIT margin at 6.6%, unchanged from 6.5% prior year.

GRASIM – Grasim Industries – Q4 FY26 Financial Results – 20-May-26

Grasim’s FY26 delivered 32.8% PAT growth, 130 bps EBIT margin expansion, and Building Materials scale milestone. Risks: structural cash consumption, NBFC/HFC growth masking credit risk, and negative FCF. Re‑rating hinges on Building Materials margin inflection, debt trajectory, and NBFC asset quality disclosures alongside consolidated PAT.

1–2 minutes

🔍 Observations

Topline

Consolidated revenue from operations surged 18.2% YoY (₹1,48,478 Cr → ₹1,75,431 Cr), led by Building Materials (+24.3%) and Financial Services (+11.8%) — both structurally large segments with compounding scale.
Q4FY26 revenue hit ₹51,101 Cr, up 15.4% YoY and 15.3% QoQ, suggesting Q4 seasonality tailwinds and demand acceleration in cement/paints.
Building Materials contributed ₹1,01,202 Cr (57.7% of segment revenue) — crossed the ₹1 lakh Cr milestone for the first time, reflecting UltraTech + Birla Opus scale-up.

Bottomline

Net profit jumped 32.8% YoY (₹7,756 Cr → ₹10,300 Cr); Q4FY26 alone delivered ₹3,802 Cr, up 27.9% YoY — strongest quarterly print.
EPS expanded from ₹55.57 to ₹73.21 (basic), a 31.7% YoY jump on a stable share count — purely earnings-driven, not dilution.
Total tax expense rose 35.9% YoY, absorbing some profit upside; effective tax rate held near 28.8% — slightly elevated but not alarming.

Margins

Consolidated EBIT margin (segment EBIT / segment revenue): ₹25,693 Cr on ₹1,77,217 Cr = 14.5% vs 13.2% in FY25 — 130 bps expansion YoY.
Building Materials EBIT grew 36.2% (₹12,012 Cr → ₹16,364 Cr) on 24.3% revenue growth — operating leverage clearly visible; this segment is the primary margin engine.
Net profit margin (PAT / Revenue from Ops): 10,300 / 1,75,431 = 5.87% vs 5.22% in FY25 — 65 bps improvement, meaningful for a conglomerate of this size.

Growth Trajectory

Cellulosic Fibres EBIT: +14.9% YoY (₹1,524 Cr → ₹1,751 Cr) on 7.6% revenue growth — margin improvement driving profitability, not just volume.
Financial Services EBIT: +13.8% YoY (₹4,650 Cr → ₹5,293 Cr) — NBFC/HFC loan book growing, finance costs rising in tandem but EBIT spread holding.
Chemicals EBIT: +16.4% YoY (₹1,208 Cr → ₹1,406 Cr) — steady contributor, not high-growth but consistent.

TDPOWERSYS – TD Power Systems – Q4 FY26 Earnings Call – 15-May-26

TD Power Systems’ topline driven by export demand (AI/data centers, renewables), bottomline supported by margin reversion post-Turkey one-off, and margins stable at 34%+ barring commodity shocks.

1–2 minutes

Also see: TDPOWERSYS – TD Power Systems – Q4 FY26 Financial Results – 14-May-26

3-Scenario Framework

📊 Base Case (60% Probability)

Key Variables: Execution stability, commodity neutrality, order inflow at +20–25% YoY.
Outlook: INR 24B revenue (FY27), 34%+ gross margins, INR 32B capacity by FY28. AI/data center demand sustains growth; large generator ramp-up from Calendar 2028. FX and hedges offset copper spikes.

KAYNES – Kaynes Technology India – Q4 FY26 Earnings Call – 14-May-26

Kaynes Technology’s topline growth hinges on metering execution and OSAT/PCB scale, while margins and cash flows are structurally pressured by working capital and amortization until H2 FY27.

1–2 minutes

Also see: KAYNES – Kaynes Technology India – Q4 FY26 Financial Results – 13-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Metering receivables reduce 70% in 3 quarters, OSAT/PCB at guidance (INR550-700 crore), automotive grows at 10%.
Outcome: Revenue INR4,000-4,200 crore in FY27, EBITDA margins 15-16%, OCF breakeven by Q4 FY27. Diversification offsets cyclical weakness, but execution risks persist.

TVSMOTOR – TVS Motor Company – Q4 FY26 Earnings Call – 13-May-26

TVS Motor’s topline growth hinges on export momentum and EV scaling, while margins depend on commodity offsets and premium mix; structural tailwinds (capacity, R&D, partnerships) outweigh cyclical risks if execution holds.

1–2 minutes

Also see: TVSMOTOR – TVS Motor Company – Q4 FY26 Financial Results – 13-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Commodity inflation at 3–5%, supply chain resolves by H1 FY27, EV penetration at 8–9%, export growth at 15–20%.
Outcome: Revenue grows 10–12% YoY, EBITDA margin sustains at 13%, and EV revenue reaches ~INR 7,000 crore. Capex execution on track; margin stability via price hikes and mix.

TEXRAIL – Texmaco Rail & Engineering – Q4 FY26 Earnings Call – 13-May-26

Texmaco Rail & Engineering/ TEXRAIL’s topline growth hinges on tender execution and export scaling, while margins depend on cost pass-through and mix shift; Texmaco 2.0’s success (defense/AI) is the swing factor for long-term re-rating.

1–2 minutes

Also see: TEXRAIL – Texmaco Rail & Engineering – Q4 FY26 Financial Results – 12-May-26

3-Scenario Framework

📊 Base Case (60% Probability)

Key Variables: (1) Indian Railways tenders materialize in tranches (Q3 FY27), (2) Supply chain normalizes by H2 FY27.
Outlook: Revenue grows 10–15% YoY in FY27 (export orders + private sector), EBITDA margins sustain at 10–11% (cost controls + mix shift). Defense/AI capex begins in FY27, but contribution to FY27 earnings minimal. Net debt/equity remains <0.2.

GRSE – Garden Reach Shipbuilders – Q4 FY26 Earnings Call – 12-May-26

Garden Reach Shipbuilders/ GRSE’s topline growth hinges on NGC/P-17 Bravo timelines and export traction, while margins depend on defense mix and cost controls; base case supports 10–12% EBITDA margins with double-digit revenue growth.

1–2 minutes

Also see: GRSE – Garden Reach Shipbuilders – Q4 FY26 Financial Results – 28-Apr-26

3-Scenario Framework

📊 Base Case (50% Probability)

NGC signed in Q2FY27, P-17 Bravo contract by FY27-end, and 1 export order in FY27. Revenue grows 12–15% CAGR (FY26–28) with EBITDA margins at 10–11%. Order book stabilizes at INR 20,000 crore by FY28, supported by defense RFPs and marginal commercial wins.

BEL – Bharat Electronics – Q4 FY26 Financial Results – 19-May-26

BEL/ Bharat Electronics’ FY26 delivered 16.2% revenue and 13.9% PAT growth with debt‑free balance sheet and improving OCF, confirming defence capex cycle strength. Risks: 43 bps margin compression, opex outpacing revenue, thin ~9% FCF, and ₹12,87,576L receivables. FY27 re‑rating hinges on receivable resolution and WC signals.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 16.2% YoY (₹23,76,875L → ₹27,61,011L), with Q4FY26 alone at ₹10,22,443L — a 11.8% beat over Q4FY25’s ₹9,14,959L, confirming back-half loading.
Sequential Q4 surge (₹7,15,385L in Q3 → ₹10,22,443L) reflects typical defence order execution bunching in year-end quarter.
Other income declined sharply YoY (₹74,236L → ₹56,603L), pulling total income growth slightly below revenue growth at 14.9%.

Bottomline

Net profit grew 13.9% YoY (₹5,32,268L → ₹6,06,226L); Q4FY26 PAT of ₹2,22,635L surpassed Q4FY25’s ₹2,12,702L by 4.7%.
Effective tax rate eased to 25.2% vs 25.5% in FY25, aided by deferred tax credit of ₹3,491L (vs ₹4,150L charge in FY25) — meaningful swing.
EPS rose from ₹7.28 to ₹8.29 (+13.9%), fully diluted, on unchanged share capital.

Margins

EBIT (PBT ex-other income, ex-finance cost): ₹27,61,011L revenue vs PBT ₹8,05,296L less other income ₹56,603L plus finance cost ₹673L = operating profit ₹7,49,366L → EBIT margin ~27.1% vs prior year: ₹7,09,900L – ₹74,236L + ₹968L = ₹6,36,632L on ₹23,76,875L → 26.8%. Marginal expansion of ~30 bps.
Net profit margin: ₹6,06,226L ÷ ₹27,61,011L = 21.96% vs ₹5,32,268L ÷ ₹23,76,875L = 22.39% — slight 43 bps compression, driven by faster opex growth.
Employee costs grew faster than revenue (12.9% → ₹3,11,555L); other expenses jumped 21.4% (₹1,98,719L → ₹2,41,208L), indicating cost base expanding ahead of topline.

Growth Trajectory

16.2% revenue CAGR (1-year) on a large base signals continued defence capex tailwinds; order book execution is accelerating.
PAT growth lagging revenue growth (13.9% vs 16.2%) — margin dilution risk if opex inflation persists.
Q4 concentration (~37% of FY revenue) remains a structural feature; execution risk is high if year-end order flows are delayed.

ZYDUSLIFE – Zydus Lifesciences – Q4 FY26 Financial Results – 19-May-26

Zydus’ FY26 shows EBITDA margin expansion and Pharma EBIT at multi‑year highs, but acquisitions flipped net cash to net debt, collapsed OCF, and added loss‑making Med Tech and Consumer units. FY27 re‑rating hinges on OCF recovery, debt reduction, and margin inflection in new segments.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 16.8% YoY (₹232,415 Mn → ₹271,484 Mn), led by Pharma (₹205,415 Mn → ₹224,121 Mn, +9.1%) and a near-doubling of Consumer Products (₹26,976 Mn → ₹39,540 Mn, +46.6%).
Medical Technologies contributed ₹7,823 Mn in FY26 vs ₹24 Mn in FY25 — full-year impact of an acquired business.
Q4FY26 revenue of ₹75,870 Mn was up 16.2% YoY vs Q4FY25 (₹65,279 Mn), with sequential improvement from Q3FY26 (₹68,645 Mn).

Bottomline

Net profit grew 11.3% YoY (₹45,255 Mn → ₹50,400 Mn); exceptional items of ₹5,166 Mn (vs ₹2,196 Mn in FY25) weighed on reported PAT.
Pre-exceptional PBT rose 14.3% YoY (₹62,463 Mn → ₹71,377 Mn) — underlying earnings quality remains strong.
Effective tax rate dropped meaningfully: 23.4% in FY26 vs 23.4% in FY25 — stable, no distortion from deferred tax movements at the net level.

Margins

EBITDA proxy (PBT before exceptional + D&A + Finance costs): ₹71,377 + ₹14,080 + ₹4,389 = ₹89,846 Mn on revenue of ₹271,484 Mn → EBITDA margin ~33.1% vs ₹62,463 + ₹9,158 + ₹1,699 = ₹73,320 Mn on ₹232,415 Mn → 31.5% in FY25. ~160 bps expansion YoY.
Net profit margin: ₹50,400 / ₹271,484 = 18.6% vs ₹45,255 / ₹232,415 = 19.5% — 90 bps compression, driven by higher D&A (₹14,080 Mn vs ₹9,158 Mn) and finance costs (₹4,389 Mn vs ₹1,699 Mn) post-acquisitions.
Consumer Products EBIT margin compressed sharply: ₹2,671 / ₹39,540 = 6.8% vs ₹3,470 / ₹26,976 = 12.9% — the acquired business is dilutive at EBIT level.

Growth Trajectory

3-year revenue compounding is intact; FY26’s 16.8% growth is above-industry for a company of this scale.
Pharma segment — the core engine — delivered only 9.1% growth; incremental revenue acceleration depended heavily on acquisitions.
Medical Technologies segment is loss-making (EBIT: -₹1,782 Mn) and rapidly scaling costs — trajectory unclear without further disclosure.

SOLARINDS – Solar Industries India – Q4 FY26 Earnings Call – 15-May-26

Solar Industries’topline growth is defense/international-led, margins hinge on commodity pass-through and mix, and bottomline resilience depends on subsidiary execution and working capital normalization.

1–2 minutes

Also see: SOLARINDS – Solar Industries India – Q4 FY26 Financial Results – 15-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Defense hits INR4,500 crores, international grows 25%, and domestic recovers modestly. Commodity lag pressures Q1 margins, but full-year EBITDA holds at 27–28%. Revenue: INR14,000 crores, EPS growth: 10–12%.